ZN-c5 / Zentalis Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ZN-c5 / Zentalis Pharma
ZN-c5-001, NCT03560531 / 2018-001364-27: A Study of ZN-c5 in Subjects With Breast Cancer

Completed
1/2
181
Europe, US, RoW
ZN-c5, Palbociclib, IBRANCE®
Zeno Alpha Inc.
Breast Cancer
04/22
12/22

Download Options